

Children's Mercy Kansas City

SHARE @ Children's Mercy

Research Days

GME Research Days 2022

May 6th, 11:30 AM - 1:30 PM

Memory T cell Populations in Human Leukemia

Sara McElroy

Children's Mercy Kansas City

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/researchdays>



Part of the [Higher Education and Teaching Commons](#), [Medical Education Commons](#), [Neoplasms Commons](#), [Pediatrics Commons](#), and the [Science and Mathematics Education Commons](#)

McElroy, Sara, "Memory T cell Populations in Human Leukemia" (2022). *Research Days*. 5.

https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2022/ResearchDay5/5

This Poster Presentation is brought to you for free and open access by the Conferences and Events at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Memory T Cell Populations in Human Leukemia

Sara McElroy, MD; Fang Tao, MD/PhD; John Szarejko, PhD; John Perry, PhD

Children's Mercy Kansas City; Children's Mercy Research Institute

Background

- Knowledge about the nature of T cells in cancer, particularly memory T cells, is vital prior to potential incorporation into immunotherapies for leukemia such as:
 - Immune checkpoint inhibitors
 - Bispecific T-cell engagers
 - Chimeric antigen receptor (CAR) tumor-specific T cells
- T cells are made up of diverse subpopulations including **memory CD8+ T cells** which are further classified into **central memory T cells (T_{cm})**, **effector memory T cells (T_{em})**, and **T memory stem cells (T_{scm})**.
- T_{scm}**, the most recently characterized of these is of interest due to its:
 - Longevity
 - Self-renewal properties
 - Ability to create the full spectrum of memory CD8+ T cells
- Objective:** To determine potential presence and frequency of memory T cell populations in human leukemia at diagnosis and after induction chemotherapy.




Stemness	Senescence
Proliferative potential	Cytotoxicity
Lymphoid homing	Tissue tropism
Antigen independence	Antigen addiction
Lipid metabolism	Glycolytic metabolism
Low Δψ _m	Oxidative stress

Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. *Nat Med.* 2017;23(1):18-27. doi:10.1038/nm.4241

Methods

- Children's Mercy Cancer Center Biorepository provided samples from 16 patients with **premature B cell acute lymphoblastic leukemia (pre-B ALL)** from peripheral blood (PB) and/or bone marrow (BM).
- Timepoints were at diagnosis and day 29 (D29) of induction chemotherapy.
- Flow cytometric analysis of cytotoxic memory T cell populations was performed and analyzed using descriptive statistics and the t-test.


Gating Strategy



Results

- The absolute cell counts were not significantly different between diagnosis and D29.
- The live cell percent was lower at diagnosis than D29 (PB- 57.2% vs 79.4%, p=0.001; BM- 41.7% vs 77.0%, p<0.001).
- T cell frequencies were lower at D29 (PB- 14.8% vs 5.74%, p=0.014; BM- 9.5% vs 5.9%, p=0.217).
- CD4+ T cells and CD8+ T cells were not significantly different between diagnosis and D29.
- Among CD8+ T cells, **naïve cells markedly increased from diagnosis to D29** (PB- 53.6% vs 82.2%, p<0.001; BM- 38.8% vs 80.3%, p<0.001) with a corresponding **significant decrease in Tem** (PB- 15.1% vs 4.2%, p=0.002; BM- 21.6% vs 4.7%, p<0.001).
- T_{scm} (reported as a percentage of CD8+ T cells) were detected in all samples at diagnosis (PB range- 0.49-12.2%; BM range- 0.12-4.4%).
- After induction chemotherapy, two patients had no T_{scm} detected. The remainder demonstrated varying numbers of T_{scm} (PB range- 0.038-23.4%; BM range- 0.013-17.4%).
- Differences between diagnosis and D29 were not significant; however, **percentages of T_{scm} were lower in 9 of 12 patients after chemotherapy.**

Results (cont.)



Conclusions

- Induction chemotherapy led to decreased differentiated CD8+ T cells with recovery of mostly naïve cells by D29.
- Furthermore, we established the presence of T_{scm} in most pediatric pre-B ALL samples.
- The decline of T_{scm} in most patients requires functional analyses to determine their role in leukemia and potential for use in immunotherapy.
- Studies are ongoing to detect differences in memory T cell populations based on response to induction chemotherapy.
- Further study is needed to investigate the potential impact of these changes on risk of relapse.
- References available upon request
- Acknowledgement: Funding for this project was provided by Big Slick.

LOVE WILL.